Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBImAb: FOLFIRI + Bevacizumab vs Cetuximab in mCRC
NCT04776655Phase 3Active, not recruiting
- Sponsor
- Azienda USL-IRCCS di Reggio Emilia
- Start
- Apr 2021
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Azienda USL-IRCCS di Reggio Emilia. Started Apr 2021; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04776655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776655.